BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Jefferies 2013 Global Healthcare Conference to be held June 3-6, 2013 at the Grand Hyatt New York.
BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Jefferies 2013 Global Healthcare Conference to be held June 3-6, 2013 at the Grand Hyatt New York.
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research...
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research...
Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a global leader in human cord blood stem cell banking and therapeutics, announced today that StemCyte has become an associate sponsor of the No. 16 Acorn Stairlifts...
Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a global leader in human cord blood stem cell banking and therapeutics, announced today that StemCyte has become an associate sponsor of the No. 16 Acorn Stairlifts...
MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today scheduled a conference call to discuss its financial results for the second quarter of fiscal year 2013,...
MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today scheduled a conference call to discuss its financial results for the second quarter of fiscal year 2013,...
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and...
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and...
PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based...
PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based...
Saddleback Memorial Medical Center in Laguna Hills, CA recently became the first hospital on the West Coast to perform a hysterectomy using single site robotic technology. This new surgical option provides women with a...
Saddleback Memorial Medical Center in Laguna Hills, CA recently became the first hospital on the West Coast to perform a hysterectomy using single site robotic technology. This new surgical option provides women with a...
VG Energy, an agricultural biotech company, announces today a strategic alliance with DAK Renewable Research to conduct field trials using LipidMax to increase the corn oil yield. VG Energy is a majority owned subsidiary of...
VG Energy, an agricultural biotech company, announces today a strategic alliance with DAK Renewable Research to conduct field trials using LipidMax to increase the corn oil yield. VG Energy is a majority owned subsidiary of...
Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.
Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided, one in five surveyed gastroenterologists, hepatologists, and infectious...
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided, one in five surveyed gastroenterologists, hepatologists, and infectious...
Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its...
Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its...
Z Trim Holdings, Inc. (OTC Markets: ZTHO), a bio-technology company providing value-added ingredients to a variety of industries, announced that Chef Erin Ryan participated in a panel discussion at this year's National...
Z Trim Holdings, Inc. (OTC Markets: ZTHO), a bio-technology company providing value-added ingredients to a variety of industries, announced that Chef Erin Ryan participated in a panel discussion at this year's National...
Direct to implant, or "one step," breast reconstruction following mastectomy is an appropriate option for many women with BRCA (BReast CAncer) gene mutations seeking to surgically reduce their breast cancer risk, or with...
Direct to implant, or "one step," breast reconstruction following mastectomy is an appropriate option for many women with BRCA (BReast CAncer) gene mutations seeking to surgically reduce their breast cancer risk, or with...
Israel Brain Technologies (IBT) has announced the launch of BrainTech Israel 2013, Israel's 1st International Brain Technology Conference, which will take place on October 14th-15th in Tel Aviv, recently ranked as the...
Israel Brain Technologies (IBT) has announced the launch of BrainTech Israel 2013, Israel's 1st International Brain Technology Conference, which will take place on October 14th-15th in Tel Aviv, recently ranked as the...
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it will use its exhibit at this year's American...
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it will use its exhibit at this year's American...
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as...
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer. Mr. Ramsay was most recently Vice President, Corporate Development at Halozyme.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer. Mr. Ramsay was most recently Vice President, Corporate Development at Halozyme.
Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Jeffrey Black, Chief Financial Officer, will...
Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Jeffrey Black, Chief Financial Officer, will...
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2013 financial results and to provide a business update. The...
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2013 financial results and to provide a business update. The...
QUÉBEC CITY, May 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the following posters will be presented on AEZS-108, the Company's lead oncology compound, at...
QUÉBEC CITY, May 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the following posters will be presented on AEZS-108, the Company's lead oncology compound, at...
GUELPH, ON, May 23, 2013 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for the three month period ended March 31, 2013. Biorem's complete 2013 first quarter financial...
GUELPH, ON, May 23, 2013 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for the three month period ended March 31, 2013. Biorem's complete 2013 first quarter financial...
Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of targeted biological products for cancer,...
Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of targeted biological products for cancer,...
EarlySense, the market leader in Proactive Patient Care Solutions™, announced today that the prize for 'Best Novel Idea' at the 8th Annual Rapid Response Systems and Medical Emergency Teams International Conference,...
EarlySense, the market leader in Proactive Patient Care Solutions™, announced today that the prize for 'Best Novel Idea' at the 8th Annual Rapid Response Systems and Medical Emergency Teams International Conference,...
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating...
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating...
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated...
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated...
PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Jefferies Healthcare Conference in New York. James Winschel, Sr. Vice President and Chief Financial Officer, will be making...
PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Jefferies Healthcare Conference in New York. James Winschel, Sr. Vice President and Chief Financial Officer, will be making...
BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media...
BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media...
Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 87.80 percent of outstanding shares were represented at the meeting.
Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 87.80 percent of outstanding shares were represented at the meeting.
New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures...
New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart's TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures...
Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™...
Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™...
Healthcare providers are turning to OnBase, Hyland Software's enterprise content management (ECM) solution, for a deeper integration with Meditech's Hospital Information System. These organizations identified...
Healthcare providers are turning to OnBase, Hyland Software's enterprise content management (ECM) solution, for a deeper integration with Meditech's Hospital Information System. These organizations identified...
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of the Lotus™ Valve System in...
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of the Lotus™ Valve System in...
STEPh, Inc., a full service medical communications company, is pleased to announce the launch of their web site ( http://www.stephreports.com ) dedicated to investigational drug reports [STEPh Reports].
STEPh, Inc., a full service medical communications company, is pleased to announce the launch of their web site ( http://www.stephreports.com ) dedicated to investigational drug reports [STEPh Reports].
Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B...
Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B...
Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy)...
Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy)...
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from...
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from...
Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell University for use in developing a molecular diagnostic test that could help in diagnosing and...
Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell University for use in developing a molecular diagnostic test that could help in diagnosing and...
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen...
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen...
Superior Controls, Inc. has been named "Manufacturing/Technology Business of the Year 2013" by Business NH Magazine. For the past 22 years, the magazine has recognized Granite State organizations that distinguish themselves...
Superior Controls, Inc. has been named "Manufacturing/Technology Business of the Year 2013" by Business NH Magazine. For the past 22 years, the magazine has recognized Granite State organizations that distinguish themselves...
Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D., Ph.D., to its Board of...
Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D., Ph.D., to its Board of...
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver a...
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver a...
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC...
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC...
Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American...
Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American...
Celsion Corporation (NASDAQ: CLSN) announced today that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally: China,...
Celsion Corporation (NASDAQ: CLSN) announced today that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally: China,...
Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the Company is scheduled to present at the Second Annual Marcum LLP Microcap Conference, May 30, in New York, NY.
Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the Company is scheduled to present at the Second Annual Marcum LLP Microcap Conference, May 30, in New York, NY.
Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that Pnina Fishman, Chief Executive...
Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that Pnina Fishman, Chief Executive...
PRNewswire – iBio, Inc. (NYSE MKT: IBIO) today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch™ platform. This...
PRNewswire – iBio, Inc. (NYSE MKT: IBIO) today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch™ platform. This...
Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that John Reynders will...
Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that John Reynders will...
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced...
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced...
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet...
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet...
Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described...
Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described...
CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using...
CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using...
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds,...
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds,...
WomanCare Global recently launched Simplant in Chile with an extensive training initiative attended by 90 health care providers.
WomanCare Global recently launched Simplant in Chile with an extensive training initiative attended by 90 health care providers.
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical...
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical...
On May 9, 2013, FTI Consulting, Inc. (NYSE: FCN), the global business advisory firm dedicated to helping organizations protect and enhance their enterprise value (the "Company"), announced that it has combined the healthcare...
On May 9, 2013, FTI Consulting, Inc. (NYSE: FCN), the global business advisory firm dedicated to helping organizations protect and enhance their enterprise value (the "Company"), announced that it has combined the healthcare...
QUEBEC CITY, May 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), announced today that it has entered into an "At Market" Issuance ("ATM") Sales Agreement, dated May 21, 2013, with MLV...
QUEBEC CITY, May 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), announced today that it has entered into an "At Market" Issuance ("ATM") Sales Agreement, dated May 21, 2013, with MLV...
The Lindsley F. Kimball Research Institute of the New York Blood Center announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Dr. Sara Lustigman,...
The Lindsley F. Kimball Research Institute of the New York Blood Center announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Dr. Sara Lustigman,...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market LCP-Tacro for the prevention of...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market LCP-Tacro for the prevention of...
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer...
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer...
On its tenth anniversary Pi2 introduced its new corporate image and impressive new product developments at the Special Libraries Association PHTD meeting in Philadelphia. "After ten years of unerring focus on product...
On its tenth anniversary Pi2 introduced its new corporate image and impressive new product developments at the Special Libraries Association PHTD meeting in Philadelphia. "After ten years of unerring focus on product...
Masimo (NASDAQ: MASI) announced today that a new clinical study posted online in Respiratory Care confirms the clinical utility of Masimo's noninvasive carboxyhemoglobin (SpCO®) from rainbow® Pulse CO-Oximetry™ as a...
Masimo (NASDAQ: MASI) announced today that a new clinical study posted online in Respiratory Care confirms the clinical utility of Masimo's noninvasive carboxyhemoglobin (SpCO®) from rainbow® Pulse CO-Oximetry™ as a...
The congress of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. Nearly 10,000 participants are in...
The congress of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. Nearly 10,000 participants are in...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging agent on key efficacy endpoints, including overall survival and...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging agent on key efficacy endpoints, including overall survival and...
IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece....
IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece....
Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound platform, today announced the introduction of the cQuest Ultrasound SDK™ Client/Server Toolkit that allows complete network-based...
Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound platform, today announced the introduction of the cQuest Ultrasound SDK™ Client/Server Toolkit that allows complete network-based...
Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of James S. MacDonald, PhD, DABT to the...
Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of James S. MacDonald, PhD, DABT to the...
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, Life Science Research, IVD...
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, Life Science Research, IVD...
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine published online the positive Phase 2a study results of dupilumab...
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine published online the positive Phase 2a study results of dupilumab...
Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the...
Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the...
Healthcare organizations expanding into emerging markets like Brazil, Russia, India and China (BRIC) are realizing there are no shortcuts. This is proving particularly challenging, considering the current healthcare...
Healthcare organizations expanding into emerging markets like Brazil, Russia, India and China (BRIC) are realizing there are no shortcuts. This is proving particularly challenging, considering the current healthcare...
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced...
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced...
Personal Genome Diagnostics Inc. (PGDx), today announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with...
Personal Genome Diagnostics Inc. (PGDx), today announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with...
MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein,"...
MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein,"...
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 2nd Annual Marcum LLP...
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 2nd Annual Marcum LLP...
Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today announced that CX50 xMATRIX, the world's first portable ultrasound with Philips' industry leading Live 3D TEE, now offers 2-D Intracardiac Echo (ICE) capability....
Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today announced that CX50 xMATRIX, the world's first portable ultrasound with Philips' industry leading Live 3D TEE, now offers 2-D Intracardiac Echo (ICE) capability....
Today, at the American Psychiatric Association (APA) Meeting in San Francisco, James McGough, M.D., M.S., principal investigator and Professor of Clinical Psychiatry at the Semel Institute for Neuroscience and Human Behavior...
Today, at the American Psychiatric Association (APA) Meeting in San Francisco, James McGough, M.D., M.S., principal investigator and Professor of Clinical Psychiatry at the Semel Institute for Neuroscience and Human Behavior...
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has secured...
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has secured...
(PSHR) Pacific Shore Holdings, Inc. a consumer products company providing naturally based products across a broad range of product categories lines, today reports that the company has retained investor relations firm,...
(PSHR) Pacific Shore Holdings, Inc. a consumer products company providing naturally based products across a broad range of product categories lines, today reports that the company has retained investor relations firm,...
Dr. Gerald Zon, noted scientist in the field of nucleic acid research, recently launched a new blog in conjunction with TriLink BioTechnologies. The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's...
Dr. Gerald Zon, noted scientist in the field of nucleic acid research, recently launched a new blog in conjunction with TriLink BioTechnologies. The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's...
Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to increase its offer for Elan Corporation, plc (NYSE: ELN) to...
Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to increase its offer for Elan Corporation, plc (NYSE: ELN) to...
Pacific Biomarkers and Clinigene International are set to unveil their collaborative laboratory solutions for developers of biosimilars at the 2013 AAPS/ National Biotechnology Conference May 20-22 at the Sheraton San Diego...
Pacific Biomarkers and Clinigene International are set to unveil their collaborative laboratory solutions for developers of biosimilars at the 2013 AAPS/ National Biotechnology Conference May 20-22 at the Sheraton San Diego...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on...
The May 2013 issue of Pharmacy Practice News (Volume 40) features an article sponsored by Intelligent Hospital Systems, and authored by Steve Frandzel with the title of "A Tale of Two IV Robots", comparing both IV...
The May 2013 issue of Pharmacy Practice News (Volume 40) features an article sponsored by Intelligent Hospital Systems, and authored by Steve Frandzel with the title of "A Tale of Two IV Robots", comparing both IV...
Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as...
Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as...
Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis in type 1 diabetic patients. The trial demonstrated that...
Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis in type 1 diabetic patients. The trial demonstrated that...
Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms among diabetic patients in the U.S. than previously recognized. Prevalence of these...
Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms among diabetic patients in the U.S. than previously recognized. Prevalence of these...
TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, announced its common stock is trading on the...
TNI BioTech, Inc. (OTCQB: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, announced its common stock is trading on the...
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting...
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting...
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the latest release of the Accelrys Electronic Lab Notebook (AELN), which now offers extensive...
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the latest release of the Accelrys Electronic Lab Notebook (AELN), which now offers extensive...
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its...
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its...
Intercept Pharmaceuticals, Inc. ("Intercept", NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced...
Intercept Pharmaceuticals, Inc. ("Intercept", NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced...
Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology...
Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology...
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced that Chief...
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced that Chief...
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it presented...
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it presented...
Mandacaru field trial report - press summary Oxitec's ground-breaking approach to pest control has again been demonstrated in a further trial carried out by Moscamed in Brazil. In this trial Moscamed achieved a 96%...
Mandacaru field trial report - press summary Oxitec's ground-breaking approach to pest control has again been demonstrated in a further trial carried out by Moscamed in Brazil. In this trial Moscamed achieved a 96%...
eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing. eFFECTOR is focused on inventing and developing small molecule drugs to selectively...
eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing. eFFECTOR is focused on inventing and developing small molecule drugs to selectively...
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today ...
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today ...
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically...
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically...
